Key Beta Thalassemia Treatment Market Players:
- Bluebird Bio Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Acceleron Pharma, Inc.
- Celgene Corporation
- GlaxoSmithKline plc
- Incyte Corporation
- Gamida Cell
- Kiadis Pharma
- La Jolla Pharmaceutical Company
- Vertix Pharmaceuticals Incorporated
- ApoPharma Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of beta thalassemia treatment is assessed at USD 541.45 million.
The global beta thalassemia treatment market size surpassed USD 509.36 million in 2025 and is projected to witness a CAGR of over 7%, crossing USD 1 billion revenue by 2035.
The North America is projected to hold a 33% share by 2035 in the beta thalassemia treatment market, driven by robust R&D activities and the growing presence of key market players.
Key players in the market include Honeywell International Inc., Doosan Corporation., Siemens, General Electric, Flowserve Corporation.
